Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
about
Unraveling oxyntomodulin, GLP1's enigmatic brotherImpact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis.α-Glucosidase inhibitors and their use in clinical practiceMetformin and its clinical use: new insights for an old drug in clinical practice.Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus.Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures.Advances in pharmacologic therapies for type 2 diabetes.Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.Sulfonylureas and their use in clinical practice.DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control.Treatment of diabetes using traditional Chinese medicine: past, present and future.Quantitative Evaluation of Compliance with Recommendation for Sulfonylurea Dose Co-Administered with DPP-4 Inhibitors in Japan.A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus.Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function.Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation.Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study.Commentary on "Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force".Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes
P2860
Q27001704-74361924-2470-48CB-9379-71CD54A84F16Q36202964-039A367B-4E5E-414C-9A19-A795136E3FEEQ36423072-DC73BA85-6239-4880-8377-99F7C7FD6B48Q36423076-64091A8B-E6D0-4A2A-973A-063CC1B669CAQ36428096-B85B301C-70B9-4989-B360-26227997A8F6Q37468396-9C94C2B7-4F79-4D5B-8E42-8BB0D516A2F9Q38072616-417DF1AE-6DB0-4526-B795-27EC1A4FA638Q38219480-8F4D22A7-178A-4E97-95AD-0E1C20F8F94FQ38527138-6C551E88-C99C-4132-9E0C-9B6B9D1CCCECQ38577058-B83A528D-8006-4597-91FF-612690E65F39Q38922177-1B747D43-43E5-4CA3-A2EF-BEC3D5283EA3Q39562298-355A3C11-4558-48FA-A8CD-DE30F65B7D11Q42876103-97E9053A-BA17-442C-98EE-E198997ED0BFQ43612314-6108BBDC-648D-4205-90C5-9C05EC05A710Q50929003-BA1965CC-AAF0-4675-919E-CF6503E9F364Q51313958-F9ACF584-9D64-4302-8210-42B6FB778B0DQ51322645-52747FB3-EE66-483E-AC4F-661544A39738Q51349530-3F09C7D1-3373-4976-871F-6E220D11E33EQ51350362-5EB656D4-E337-4F54-9943-EDA7FDA5ADC7Q51350631-CE5C2930-FA19-49BE-906F-CA00AD3097CDQ51357618-906BD68C-E0C1-4C1F-BDAE-722DB07E6536Q53827413-EB2E0E45-1B49-495F-849D-90320EFA13FBQ55344735-8A5086A7-BB21-426D-AA8B-539ED5B15BB3Q57563922-3A4CD72F-32E8-4F19-9196-D274DBF1E4FE
P2860
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@en
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@nl
type
label
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@en
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@nl
prefLabel
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@en
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
@nl
P356
P1476
Dipeptidyl peptidase-4 inhibitors: 3 years of experience
@en
P2093
Giuseppe Derosa
Pamela Maffioli
P304
P356
10.1089/DIA.2011.0204
P577
2012-02-10T00:00:00Z